REGN Key Statistics, Chart & Performance
The current stock price of REGN is 755.02 USD. In the past month the price decreased by -2.74%. In the past year, price increased by 6.34%.
REGN Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to REGN. When comparing the yearly performance of all stocks, REGN turns out to be only a medium performer in the overall market: it outperformed 68.25% of all stocks.
REGN Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to REGN. REGN gets an excellent profitability rating and is at the same time showing great financial health properties.
REGN Financial Highlights
Over the last trailing twelve months REGN reported a non-GAAP Earnings per Share(EPS) of 44.38. The EPS decreased by -2.76% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 32.13% | ||
| ROA | 11.4% | ||
| ROE | 14.79% | ||
| Debt/Equity | 0.09 |
REGN Forecast & Estimates
36 analysts have analysed REGN and the average price target is 838.03 USD. This implies a price increase of 10.99% is expected in the next year compared to the current price of 755.02.
For the next year, analysts expect an EPS growth of 4.14% and a revenue growth 6.89% for REGN
REGN Ownership
REGN Latest News, Press Relases and Analysis
About REGN
Company Profile
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. The company is headquartered in Tarrytown, New York and currently employs 15,106 full-time employees. The firm invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The firm is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.
Company Info
REGENERON PHARMACEUTICALS
777 Old Saw Mill River Road
Tarrytown NEW YORK 10591 US
CEO: Leonard S. Schleifer
Employees: 15106
Phone: 17813705000
REGENERON PHARMACEUTICALS / REGN FAQ
Can you describe the business of REGENERON PHARMACEUTICALS?
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. The company is headquartered in Tarrytown, New York and currently employs 15,106 full-time employees. The firm invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The firm is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.
What is the stock price of REGENERON PHARMACEUTICALS today?
The current stock price of REGN is 755.02 USD. The price increased by 1.83% in the last trading session.
What is the dividend status of REGENERON PHARMACEUTICALS?
REGENERON PHARMACEUTICALS (REGN) has a dividend yield of 0.51%. The yearly dividend amount is currently 0.
How is the ChartMill rating for REGENERON PHARMACEUTICALS?
REGN has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
What is the Price/Earnings (PE) ratio of REGENERON PHARMACEUTICALS (REGN)?
The PE ratio for REGENERON PHARMACEUTICALS (REGN) is 17.01. This is based on the reported non-GAAP earnings per share of 44.38 and the current share price of 755.02 USD.
What is the market capitalization of REGN stock?
REGENERON PHARMACEUTICALS (REGN) has a market capitalization of 79.35B USD. This makes REGN a Large Cap stock.
Can you provide the ownership details for REGN stock?
You can find the ownership structure of REGENERON PHARMACEUTICALS (REGN) on the Ownership tab.